This bill (SB 570) allocates $199,476,099 in unspent federal funds to the West Virginia Department of Health's "Rural Health Transformation Program" for fiscal year 2026. It adds a new funding line (Fund 8802, Org 0506) under the Department's Central Office to support this specific program. The funds are designated for rural health initiatives and directly affect the Department of Health's ability to implement these programs. This is a procedural funding measure, not a policy change, using existing federal funds without new tax implications.
HB 5074 changes how revenue from West Virginia's medical cannabis program is allocated. For fiscal year 2026, it directs $3 million to the Supreme Court for a child protection pilot, $10 million each to West Virginia University and Marshall University for ibogaine research, and $5 million to homelessness services, with remaining funds reverting to general revenue. Starting July 1, 2026, annual allocations will be: 15% to the Medical Cannabis Bureau for administration, 15% to the Department of Agriculture for cannabis testing, and 45% split among the Fight Substance Abuse Fund (20%), university research (10% each to Marshall and WVU), a Child Protection Commission (10%), and law enforcement training programs (40%). These changes apply to ongoing revenue from medical cannabis taxes, not new taxes or fees.
HB 4626 establishes a West Virginia grant program to fund U.S. Food and Drug Administration (FDA) drug development trials using ibogaine, a substance being studied for treating opioid use disorder and other neurological/mental health conditions. The program requires applicants (e.g., pharmaceutical companies or research organizations) to demonstrate capacity to conduct FDA trials, secure approval for ibogaine as a medication, and commit to establishing a state presence, securing insurance coverage, and ensuring treatment access for uninsured patients. Applicants must submit detailed trial designs, safety protocols, and plans for intellectual property rights and post-approval implementation, with grants administered through a state selection committee. The bill does not approve ibogaine but aims to accelerate its development pathway through state-funded trials.
SB 649 requires West Virginia Medicaid to cover home blood pressure monitoring devices for specific enrollees: pregnant individuals or those within 12 months postpartum who have been diagnosed with uncontrolled hypertension. The bill mandates that covered devices must be validated by the U.S. Blood Pressure Validated Listing and includes coverage for an extra blood pressure cuff. Medicaid providers must also receive reimbursement for related services, such as patient training, interpreting readings, and delivering co-interventions. This policy directly affects Medicaid recipients with hypertension during pregnancy or postpartum, expanding access to essential monitoring tools.
SB 773 would require the West Virginia Department of Health to propose rules adding alpha-gal syndrome to the list of diseases that must be reported to the Centers for Disease Control and Prevention (CDC). Alpha-gal syndrome causes allergic reactions to red meat and is often triggered by tick bites. If enacted, healthcare providers in West Virginia would be required to report confirmed cases of this condition to the state health department, which would then share the data with the CDC. This change would improve public health tracking of alpha-gal syndrome cases in the state.
SB 805 adds "abortion pill reversal" to West Virginia's Mothers and Babies Pregnancy Support Program, allowing funding for this service through eligible pregnancy help organizations. The bill defines "abortion pill reversal" as using progesterone to counteract the abortion pill (mifepristone) and specifies that only organizations that do not support or perform abortions can receive program funds for this purpose. Abortion industry organizations are explicitly excluded from receiving these funds. This is a procedural change to the existing program's funding eligibility, not a new law restricting abortion access.
SB 778 amends West Virginia law to allow nurse practitioners and physician assistants, alongside physicians, to certify students with disabilities as eligible for homebound educational services. This change directly affects families of exceptional children who require homebound instruction due to injury or health conditions. The key provision removes the previous restriction requiring certification only by physicians, expanding who can authorize this service. The bill aims to streamline access to homebound education by broadening the pool of qualified medical professionals who can make this determination.
SB 1036 modernizes foster care funding in West Virginia by requiring the Department of Human Services to update basic, special, and therapeutic foster care payment rates using current cost data. It mandates automatic annual adjustments based on the Employment Cost Index (ECI) for Health Care & Social Assistance or the CPI-Medical index to keep pace with rising costs. The bill also requires therapeutic foster care and agency administrative rates to reflect current expenses and includes retention incentives for foster care providers. This directly affects foster parents, child-placing agencies, and the Department of Human Services by stabilizing workforce compensation and placement continuity. The changes aim to improve recruitment and retention in the child welfare system through updated, cost-based funding.
Senate Bill 956 removes requirements that physician assistants (PAs) in West Virginia must work under direct physician supervision or collaboration. It allows PAs to own medical businesses, practice independently without mandated supervision, and be held to the same standard of care as other licensed healthcare providers. The bill amends specific sections of West Virginia law (§30-3-14, §30-3-15, §31B-13-1301) and adds a new section (§30-3E-21) to formalize these changes, including classifying PAs as a "professional service" under business law. This directly affects PAs by expanding their scope of practice and business ownership opportunities.
SB 1012 amends West Virginia law to permit the development of 60 additional inpatient substance use disorder treatment beds specifically for youth aged 17 or younger in Cabell County. The bill modifies certificate of need requirements that previously restricted new beds in counties with over 250 existing substance abuse treatment beds, making an exception for Cabell County's juvenile beds. This policy change directly affects minors in Cabell County seeking inpatient treatment for substance use disorders by removing a regulatory barrier to expanding specialized care. The provision is limited to inpatient treatment beds exclusively for individuals 17 years or younger.
